BLB&B Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

BLB&B Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-2,536	Closed	-$31K	–	291
2014 Q1	$31K	Hold	2,536	–	–	0.01%	274
2013 Q4	$32K	Sell	2,536 -785	-24%	-$12.5K	0.01%	250
2013 Q3	$55K	Hold	3,321	–	–	0.01%	239
2013 Q2	$50K	Buy	+3,321	New	+$50.5K	0.01%	227

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

BLB&B Advisors's LXRX Position: Q2 2014 in Review

BLB&B Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2014, closing a stake of 2,536 shares — an estimated $31K sold.

BLB&B Advisors first reported a position in LXRX in Q2 2013 and held it in 4 quarters. The position peaked at $55K in Q3 2013. 99 funds tracked by Wall St. Rank hold LXRX as of Q2 2014.

BLB&B Advisors reported no remaining Lexicon Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
BLB&B Advisors sold 2,536 Lexicon Pharmaceuticals shares in Q2 2014, an estimated $31K.
BLB&B Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 4 quarters.
BLB&B Advisors's Lexicon Pharmaceuticals position peaked at $55K in Q3 2013.
99 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2014.

Based on BLB&B Advisors's 13F filing for Q2 2014, filed 17 Jul 2014.